Cyclacel Pharmaceuticals
Berkeley Heights
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $202.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nasdaq:CYCC
- Website: cyclacel.com
- Phone: +1 (908) 517 7330
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cyclacel-pharmaceuticals-148185 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.